Published: 2022-04-29 07:39 | Updated: 2022-04-29 08:59

Mattias Carlsten - new docent at KI

Congratulations to Mattias Carlsten at The Center for Hematology and Regenerative Medicine (HERM) whos has been appointed docent in hematology at MedH/KI.

Mattias Carlsten is a physician and researcher and have donated bone marrow in several studies. Photo: Lindsten & Nilsson
Mattias Carlsten at HERM, department of Medicine, Huddinge. Photo: Lindsten och Nilsson

What does the appointment mean to you?

Being appointed docent shows that my work has generated merits on a certain level, but for me the title itself is not the most important thing. First and foremost, what matters is what I contribute to in my work as a doctor, researcher and teacher.

What is your research about?

The goal of the research is to identify and develop new treatments (immunotherapies) to treat cancer and take them all the way to evaluation in patients. More specifically, I focus on how the body's immune cells can be reprogrammed so that they survive in the body. I study how immune cells migrate into the cancer-affected organ and recognize and kill the cancer, without affecting the body's healthy cells. In my research group at HERM we use modern X-ray methods (PET) to monitor these cells after they have been injected into the body. Going forward, the goal is to evaluate lab results through clinical trials with patients. It's possible to conduct the clinical studies due to my role as a doctor at the Medical Unit Cell Therapy and Allogeneic Stem Cell Transplantation (ME CAST) at the Karolinska University Hospital in Huddinge.

Why have you choosen to conduct research in hematology?

Hematology is a very exciting field, and at the same time difficult research field where development progresses rapidly on several levels. There is a great need for new forms of treatment for patients with haematological malignancies, as mortality is still very high for most diseases and treatment options are few, and broadly the same as when I started my medical education. Together with my research group, I hope to contribute to the development of immunotherapy, a treatment where the body's immune system is used to attack cancer cells.

Short bio

I studied medical education at KI (läkarprogrammet) , and defended my dissertation at KI after my research AT at Karolinska University Hospital. After that I did a post-doc with Richard Childs at NIH in the USA where I also worked as a Staff Scientist. Now I am a specialist in hematology at ME CAST, parallell to doing research with my group at HERM at KI, often in collaboration with national and international research groups. I'm also responsible for R&D (research and education) at ME CAST, where I run and co-test most clinical trials in immunotherapy against cancer.